Elsevier

Biochemical Pharmacology

Volume 38, Issue 8, 15 April 1989, Pages 1217-1229
Biochemical Pharmacology

Control of insulin secretion by sulfonylureas, meglitinide and diazoxide in relation to their binding to the sulfonylurea receptor in pancreatic islets

https://doi.org/10.1016/0006-2952(89)90327-4Get rights and content

Abstract

Sulfonylureas inhibit an ATP-dependent K+ channel in the B-cell plasma membrane and thereby initiate insulin release. Diazoxide opens this channel and inhibits insulin release. In mouse pancreatic islets, we have explored whether other targets for these drugs must be postulated to explain their hypo- or hyperglycaemic properties. At non-saturating drug concentrations the rates of increase in insulin secretion declined in the order tolbutamide = meglitinide > glipizide > glibenclamide. The same rank order was observed when comparing the rates of disappearance of insulin-releasing and K+ channel-blocking effects. The different kinetics of response depend on the lipid solubility of the drugs, which controls their penetration into the intracellular space. Allowing for the different kinetics, the same maximum secretory rates were caused by saturating concentrations of tolbutamide, meglitinide, glipizide and glibenclamide. A close correlation between insulin-releasing and K+ channel-blocking potencies of these drugs was observed. The relative potencies of tolbutamide, meglitinide, glipizide and glibenclamide corresponded well to their relative affinities for binding to islet-cell membranes, suggesting that the binding site represents the sulfonylurea receptor. The biphasic time-course of dissociation of glibenclamide binding indicates a complex receptor-drug interaction. For diazoxide there was no correlation between affinity of binding to the sulfonylurea receptor and potency of inhibition of insulin secretion. Thus, opening or closing of the ATP-dependent K+ channel by diazoxide or sulfonylureas, respectively, appears to be due to interaction with different binding sites in the B-cell plasma membrane. The free concentrations of tolbutamide, glipizide, glibenclamide and diazoxide which are effective on B-cells are in the range of therapeutic plasma concentrations of the free drugs. It is concluded that the hypo- and hyperglycaemic effects of these drugs result from changing the permeability of the ATP dependent K+ channel in the B-cell plasma membrane.

References (61)

  • J.-C. Henquin et al.

    Opposite effects of tolbutamide and diazoxide on 86Rb+ fluxes and membrane potential in pancreatic B cells

    Biochem Pharmacol

    (1982)
  • P Cuatrecasas et al.

    Membrane receptors and hormone action

    Adv Protein Chem

    (1976)
  • E.M. Ross et al.

    Relationship between the β-adrenergic receptor and adenylate cyclase. Studies of ligand binding and enzyme activity in purified membranes of S49 lymphoma cells

    J Biol Chem

    (1977)
  • E Samols et al.

    Intraislet negative insulation-glucagon feedback

    Metabolism

    (1976)
  • Y Sako et al.

    Effect of glibenclamide on pancreatic hormone release from isolated perifused islets of normal and cysteaminetreated rats

    Metabolism

    (1986)
  • M.A. Cabello et al.

    Effect of glipizide on hepatic fructose 2,6-bisphosphate concentration and glucose metabolism

    Metabolism

    (1987)
  • G Trübe et al.

    Opposite effects of tolbutamide and diazoxide on the ATPdependent K+ channel in mouse pancreatic B-cells

    Pflügers Arch

    (1986)
  • B.J. Zünkler et al.

    Concentration-dependent effects of tolbutamide, meglitinide, glipizide, glibenclamide and diazoxide on ATP-regulated K+ currents in pancreatic B-cells

    Naunyn-Schmiedeberg's Arch Pharmacol

    (1988)
  • E Gylfe et al.

    Interaction of sulfonylurea with the pancreatic B-cell

    Experientia

    (1984)
  • J.-L. Carpentier et al.

    Internalization of 3H-glibenclamide in pancreatic islet cells

    Diabetologia

    (1986)
  • G.M. Grodsky et al.

    Insulin secretion from the in vitro perfused pancreas of the rat: effect of Ro 6-4563 and other sulfonylureas

  • K Geisen et al.

    Inhibition of 3H-glibenclamide binding to sulfonylurea receptors by oral antidiabetics

    Arzneimittel-Forsch

    (1985)
  • U Panten et al.

    Recognition of insulin-releasing fuels by pancreatic B-cells. α-Ketoisocaproic acid is an appropriate model compound to study the role of B-cell metabolism

    Mol Pharmacol

    (1981)
  • A Leo et al.

    Partition coefficients and their uses

    Chem Rev

    (1971)
  • H Kubinyi

    Lipophilicity and drug activity

  • Å Lernmark

    The preparation of, and studies on, free cell suspensions from mouse pancreatic islets

    Diabetologia

    (1974)
  • P Rorsman et al.

    Glucose-dependent K+-channels in pancreatic B-cells are regulated by intracellular ATP

    Pflügers Arch

    (1985)
  • H.-G. Joost

    Effects of a possible beta-cell membrane label, metahexamide-isothiocyanate, on insulin release

    Horm Metab Res

    (1979)
  • O.P. Hamill et al.

    Improved patch-clamp techniques for highresolution current recordings from cells and cell-free membrane patches

    Pflügers Arch

    (1981)
  • Cited by (183)

    • Emerging molecular technologies for light-mediated modulation of pancreatic beta-cell function

      2022, Molecular Metabolism
      Citation Excerpt :

      Additionally, nateglinide is 1000-fold more selective for KATP+ channels in β-cells vs. cardiomyocytes. In albino mouse islets, 100 μM of tolbutamide, 1 μM of glipizide or 100 μM of meglitinide stimulates a rapid 8- to 9-fold increase of insulin secretion above basal values within 10 min in the presence of 10 mM glucose [44,45]. In pancreas, high voltage-gated Ca2+ channels (HVCCs) also play a significant role of in β-cell glucoregulatory insulin release, as the influx of calcium ions via HVCC initiate the Ca2+ -dependent exocytosis of insulin [46].

    • Berberine inhibits PTP1B activity and mimics insulin action

      2010, Biochemical and Biophysical Research Communications
      Citation Excerpt :

      We reproduced the results with both DIO mice and db/db mice that are the early type 2 diabetes model [25] and severe diabetes model respectively. Unlike the anti-diabetes drugs sulfonylureas and meglitinides that increase insulin release [26,27], BBR did not increase insulin secretion from the pancreas nor increase the synthesis of insulin, suggesting that BBR does not change pancreas biology. These data further support that BBR plays a role through activation of the insulin signaling.

    View all citing articles on Scopus

    Some results of this study were obtained during medical thesis work.

    View full text